ARTICLE | Finance
VC + CRO
Former Scandinavia Novartis CSO targets $50M for first Vanadis Capital fund
June 11, 2012 7:00 AM UTC
Swedish life sciences venture capital firm Vanadis Capital is raising its first fund and hopes to have a $50 million initial close by March 2013 and a final close at $70 million.
Vanadis' Pascal Van Peborgh told BioCentury the firm is partnering with Trial Form Support, a Swedish CRO, to glean investment leads from among TFS's clients...